Patents by Inventor Noel Harvey
Noel Harvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210402092Abstract: An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.Type: ApplicationFiled: September 9, 2021Publication date: December 30, 2021Inventors: M. Ishaq Haider, Noel Harvey, Sundeep Kankanala, Frank Martin, Ronald Pettis
-
Patent number: 11116900Abstract: An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.Type: GrantFiled: April 5, 2019Date of Patent: September 14, 2021Assignee: Becton, Dickinson and CompanyInventors: M. Ishaq Haider, Noel Harvey, Sundeep Kankanala, Frank Martin, Ronald Pettis
-
Publication number: 20190298920Abstract: An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.Type: ApplicationFiled: April 5, 2019Publication date: October 3, 2019Inventors: M. Ishaq Haider, Noel Harvey, Sundeep Kankanala, Frank Martin, Ronald Pettis
-
Patent number: 10252002Abstract: An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.Type: GrantFiled: July 30, 2015Date of Patent: April 9, 2019Assignee: Becton, Dickinson and CompanyInventors: M. Ishaq Haider, Noel Harvey, Sundeep Kankanala, Frank Martin, Ronald Pettis
-
Publication number: 20170216524Abstract: An electronic insulin delivery device receives glucose data from a glucose monitor and sets a bolus dose amount. The device may take the form of an insulin pen with automatic priming and accurate dosing provided by a motor in connection with an encoder. The device may communicate with and be controlled by a smart phone device. The smart phone device provides a user interface to receive user data including patient weight, insulin to carbohydrate ratio and exercise factor, and to send instructions to the device, including dose amount. The dose amount is determined taking into account glucose level and trend, and other factors. The delivery device may be in continuous communication with the glucose monitor and smart phone to provide for near real-time adjustments in glucose treatment. Glucose data, insulin injection data, and other relevant data may be stored and accessible to interested parties.Type: ApplicationFiled: July 30, 2015Publication date: August 3, 2017Applicant: Becton, Dickinson and CompanyInventors: M. Ishaq Haider, Noel Harvey, Sundeep Kankanala, Frank Martin, Ronald Pettis
-
Patent number: 9192750Abstract: Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.Type: GrantFiled: April 7, 2010Date of Patent: November 24, 2015Assignee: Becton, Dickinson and CompanyInventors: Ronald J. Pettis, Noel Harvey, Barry Ginsberg
-
Publication number: 20100262120Abstract: Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.Type: ApplicationFiled: April 7, 2010Publication date: October 14, 2010Applicant: Becton, Dickinson and CompanyInventors: Ronald J. Pettis, Noel Harvey, Barry Ginsberg
-
Patent number: 7722595Abstract: The invention pertains to methods and devices for controlling the pharmacokinetics of administered substances, particularly therapeutic substances by combining advantages of delivery to two or more compartments within the skin. The invention provides methods and devices for delivering substances to subcutaneous and intradermal compartments of the skin to achieve a hybrid pharmacokinetic profile that has a portion similar to that achieved by intradermal delivery, e.g., rapid and high peak onset levels of the substance, and a portion similar to that achieved by subcutaneous delivery, e.g., longer circulating levels of the substance.Type: GrantFiled: May 6, 2003Date of Patent: May 25, 2010Assignee: Becton, Dickinson and CompanyInventors: Ronald J. Pettis, Noel Harvey, Barry Ginsberg
-
Publication number: 20060264886Abstract: The present invention relates to methods for administration of insulin into the intradermal compartment of subject's skin, preferably to the dermal vasculature of the intradermal compartment. The methods of the present invention enhance the pharmacokinetic and pharmacodynamic parameters of insulin delivery and effectively result in a superior clinical efficacy in the treatment and/or prevention of diabetes mellitus. The methods of the instant invention provide an improved glycemic control of both non-fasting (i.e., post-prandial) and fasting blood glucose levels and thus have an enhanced therapeutic efficacy in treatment, prevention and/or management of diabetes relative to traditional methods of insulin delivery, including subcutaneous insulin delivery.Type: ApplicationFiled: May 6, 2004Publication date: November 23, 2006Inventors: Ronald Pettis, Noel Harvey, Barry Ginsberg
-
Publication number: 20050096632Abstract: The present invention provides improved methods for ID delivery of drugs and other substances to humans or animals. The methods employ small gauge needles, especially microneedles, placed in the intradermal space to deliver the substance to the intradermal space as a bolus or by infusion. It has been discovered that the placement of the needle outlet within the skin and the exposed height of the needle outlet are critical for efficacious delivery of active substances via small gauge needles to prevent leakage of the substance out of the skin and to improve absorption within the intradermal space. The pharmacokinetics of hormone drugs delivered according to the methods of the invention have been found to be very similar to the pharmacokinetics of conventional SC delivery, indicating that ID administration according to the methods of the invention is likely to produce a similar clinical result (i.e., similar efficacy) with the advantage of reduction or elimination of pain for the patient.Type: ApplicationFiled: December 3, 2004Publication date: May 5, 2005Inventors: Ronald Pettis, James Down, Noel Harvey
-
Publication number: 20050096631Abstract: The present invention provides improved methods for ID delivery of drugs and other substances to humans or animals. The methods employ small gauge needles, especially microneedles, placed in the intradermal space to deliver the substance to the intradermal space as a bolus or by infusion. It has been discovered that the placement of the needle outlet within the skin and the exposed height of the needle outlet are critical for efficacious delivery of active substances via small gauge needles to prevent leakage of the substance out of the skin and to improve absorption within the intradermal space. The pharmacokinetics of hormone drugs delivered according to the methods of the invention have been found to be very similar to the pharmacokinetics of conventional SC delivery, indicating that ID administration according to the methods of the invention is likely to produce a similar clinical result (i.e., similar efficacy) with the advantage of reduction or elimination of pain for the patient.Type: ApplicationFiled: December 3, 2004Publication date: May 5, 2005Inventors: Ronald Pettis, James Down, Noel Harvey
-
Publication number: 20050096630Abstract: The present invention provides improved methods for ID delivery of drugs and other substances to humans or animals. The methods employ small gauge needles, especially microneedles, placed in the intradermal space to deliver the substance to the intradermal space as a bolus or by infusion. It has been discovered that the placement of the needle outlet within the skin and the exposed height of the needle outlet are critical for efficacious delivery of active substances via small gauge needles to prevent leakage of the substance out of the skin and to improve absorption within the intradermal space. The pharmacokinetics of hormone drugs delivered according to the methods of the invention have been found to be very similar to the pharmacokinetics of conventional SC delivery, indicating that ID administration according to the methods of the invention is likely to produce a similar clinical result (i.e., similar efficacy) with the advantage of reduction or elimination of pain for the patient.Type: ApplicationFiled: December 3, 2004Publication date: May 5, 2005Inventors: Ronald Pettis, James Down, Noel Harvey
-
Publication number: 20050055010Abstract: The present invention relates to methods for administration of insulin into the intradermal compartment of subject's skin, preferably to the dermal vasculature of the intradermal compartment. The methods of the present invention enhance the pharmacokinetic and pharmacodynamic parameters of insulin delivery and effectively result in a superior clinical efficacy in the treatment and/or prevention of diabetes mellitus. The methods of the instant invention provide an improved glycemic control of both non-fasting (i.e., post-prandial) and fasting blood glucose levels and thus have an enhanced therapeutic efficacy in treatment, prevention and/or management of diabetes relative to traditional methods of insulin delivery, including subcutaneous insulin delivery.Type: ApplicationFiled: May 6, 2004Publication date: March 10, 2005Inventors: Ronald Pettis, Noel Harvey, Barry Ginsberg
-
Publication number: 20040023844Abstract: Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.Type: ApplicationFiled: May 6, 2003Publication date: February 5, 2004Inventors: Ronald J. Pettis, Noel Harvey, Barry Ginsberg